Example: tourism industry

CMS Manual System

Department of Health &. CMS Manual System Human Services (DHHS). Pub 100-04 Medicare Claims Processing Centers for Medicare &. Medicaid Services (CMS). Transmittal 3571 Date: July 29, 2016. Change Request 9674. NOTE: This Transmittal is no longer sensitive and is being re-communicated November 25, 2016. The Transmittal Number, date of Transmittal and all other information remains the same. This instruction may now be posted to the Internet. SUBJECT: New Revenue Code 0815 for Allogeneic stem Cell Acquisition Services I. SUMMARY OF CHANGES: Revenue code 0815 (Allogeneic stem Cell Acquisition Services), recently created by the National Uniform Billing Committee (NUBC), will be accepted into the Fiscal Intermediary Shared System (FISS), effective January 1, 2017 for Hospital Claims.

A. Background: Hematopoietic stem cell transplantation (HSCT) is a process that includes mobilization, harvesting, and transplant of stem cells and the administration of high dose chemotherapy and/or radiotherapy prior to the actual transplant.

Tags:

  Manual, High, System, Dose, Cells, Stem, Cms manual system, Chemotherapy, Stem cell, High dose chemotherapy

Information

Domain:

Source:

Link to this page:

Please notify us if you found a problem with this document:

Other abuse

Transcription of CMS Manual System

1 Department of Health &. CMS Manual System Human Services (DHHS). Pub 100-04 Medicare Claims Processing Centers for Medicare &. Medicaid Services (CMS). Transmittal 3571 Date: July 29, 2016. Change Request 9674. NOTE: This Transmittal is no longer sensitive and is being re-communicated November 25, 2016. The Transmittal Number, date of Transmittal and all other information remains the same. This instruction may now be posted to the Internet. SUBJECT: New Revenue Code 0815 for Allogeneic stem Cell Acquisition Services I. SUMMARY OF CHANGES: Revenue code 0815 (Allogeneic stem Cell Acquisition Services), recently created by the National Uniform Billing Committee (NUBC), will be accepted into the Fiscal Intermediary Shared System (FISS), effective January 1, 2017 for Hospital Claims.

2 EFFECTIVE DATE: January 1, 2017. *Unless otherwise specified, the effective date is the date of service. IMPLEMENTATION DATE: January 3, 2017. Disclaimer for Manual changes only: The revision date and transmittal number apply only to red italicized material. Any other material was previously published and remains unchanged. However, if this revision contains a table of contents, you will receive the new/revised information only, and not the entire table of contents. II. CHANGES IN Manual INSTRUCTIONS: (N/A if Manual is not updated). R=REVISED, N=NEW, D=DELETED-Only One Per Row.

3 R/N/D CHAPTER / SECTION / SUBSECTION / TITLE. R 4 - Billing for Allogeneic stem Cell Transplants R 3 - Billing for stem Cell Transplantation III. FUNDING: For Medicare Administrative Contractors (MACs): The Medicare Administrative Contractor is hereby advised that this constitutes technical direction as defined in your contract. CMS does not construe this as a change to the MAC Statement of Work. The contractor is not obligated to incur costs in excess of the amounts allotted in your contract unless and until specifically authorized by the Contracting Officer.

4 If the contractor considers anything provided, as described above, to be outside the current scope of work, the contractor shall withhold performance on the part(s) in question and immediately notify the Contracting Officer, in writing or by e-mail, and request formal directions regarding continued performance requirements. IV. ATTACHMENTS: Business Requirements Manual Instruction Attachment - Business Requirements Pub. 100-04 Transmittal: 3571 Date: July 29, 2016 Change Request: 9674. NOTE: This Transmittal is no longer sensitive and is being re-communicated November 25, 2016.

5 The Transmittal Number, date of Transmittal and all other information remains the same. This instruction may now be posted to the Internet. SUBJECT: New Revenue Code 0815 for Allogeneic stem Cell Acquisition Services EFFECTIVE DATE: January 1, 2017. *Unless otherwise specified, the effective date is the date of service. IMPLEMENTATION DATE: January 3, 2017. I. GENERAL INFORMATION. A. Background: Hematopoietic stem cell transplantation (HSCT) is a process that includes mobilization, harvesting, and transplant of stem cells and the administration of high dose chemotherapy and/or radiotherapy prior to the actual transplant.

6 During the process stem cells are harvested from either the patient (autologous) or a donor (allogeneic) and subsequently administered by intravenous infusion to the patient. Payment for these acquisition services is included in the OPPS APC payment for the allogeneic stem cell transplant when the transplant occurs in the hospital outpatient setting, and in the MS-DRG payment for the allogeneic stem cell transplant when the transplant occurs in the inpatient setting. The Medicare contractor does not make separate payment for these acquisition services, because hospitals may bill and receive payment only for services provided to the Medicare beneficiary who is the recipient of the stem cell transplant and whose illness is being treated with the stem cell transplant.

7 Unlike the acquisition costs of solid organs for transplant ( , hearts and kidneys), which are paid on a reasonable cost basis, acquisition costs for allogeneic stem cells are included in prospective payment. Acquisition charges for stem cell transplants apply only to allogeneic transplants, for which stem cells are obtained from a donor (other than the recipient himself or herself). Acquisition charges do not apply to autologous transplants (transplanted stem cells are obtained from the recipient himself or herself), because autologous transplants involve services provided to the beneficiary only (and not to a donor), for which the hospital may bill and receive payment (see Pub.)

8 100-04, chapter 3, and of chapter 4 for information regarding billing for autologous stem cell transplants). Currently, when the allogeneic stem cell transplant occurs in the outpatient setting, the hospital identifies stem cell acquisition charges for allogeneic bone marrow/ stem cell transplants separately in FL 42 of Form CMS-1450 (or electronic equivalent) by using revenue code 0819 (Other Organ Acquisition). Revenue code 0819 charges should include all services required to acquire stem cells from a donor, as defined above, and should be reported on the same date of service as the transplant procedure in order to be appropriately packaged for payment purposes.

9 Stakeholders have expressed concern that the acquisition costs are not being accurately reflected in the transplant procedure as Revenue Code 0819 maps to cost center code 086XX (Other organ acquisition where XX is 00 through 19 ) and is reported on line 112 (or applicable subscripts of line 112) of the Form CMS-2552-10 cost report. CMS has requested and NUBC approved a new Revenue Code 0815 to be used when the hospital identifies stem cell acquisition charges for allogeneic bone marrow/ stem cell transplants separately. B. Policy: CMS requires the reporting of revenue code 0815 for the billing of all allogeneic donor acquisition costs.

10 II. BUSINESS REQUIREMENTS TABLE. "Shall" denotes a mandatory requirement, and "should" denotes an optional requirement. Number Requirement Responsibility A/B D Shared- Other MAC M System E Maintainers A B H F M V C. H M I C M W. H A S S S F. C S. Contractors shall accept revenue codes 0815 X X X COBA, Cost (Allogeneic stem Cell Acquisition/Donor Services) Report, IOCE, into the Shared System with effective dates of service IPPS Pricer, of January 1, 2017 for 011x, 012x, 013x, and 085x bill OPPS Pricer, types. PS&R. Rev Code Subcategory Definition Standard Abbreviation Unit HCPCS.


Related search queries